First Tracks Biotherapeutics, INC

First Tracks Biotherapeutics reported Q2 2026 financial results, highlighting progress in its ANB033 clinical trials for celiac disease and eosinophilic esophagitis, alongside a positive FDA Fast Track designation.

First Tracks Biotherapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting continued investment in R&D and progress in clinical trials, alongside a significant net loss.

Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.

Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.

Daniel Faga, President, CEO and a Director of First Tracks Biotherapeutics, Inc., received 193,576 shares of common stock on August 2, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 7.2% of First Tracks Biotherapeutics, Inc. common stock.

Affinity Asset Advisors, LLC and Michael Cho have jointly reported beneficial ownership of 2,032,012 shares, representing 5.8% of First Tracks Biotherapeutics, Inc. common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership stake of 5.9% in First Tracks Biotherapeutics Inc. as of June 30, 2026.